期刊文献+

绿色荧光蛋白融合人核糖核酸酶抑制因子表达载体pEGFP-C1-hri的构建及鉴定 被引量:4

Construction and identification of expression vector for human ribonuclease inhibitor fused to green fluorescent protein
下载PDF
导出
摘要 目的构建表达绿色荧光蛋白融合人核糖核酸酶抑制因子的表达载体pEGFP-C1-hri,为探讨人核糖核酸酶抑制因子抗肿瘤作用的分子机制打下基础。方法用亚克隆法,将目的片段从表达载体pGEX-6p-1-hri克隆到pEGFP-C1上,用双酶切筛选得到阳性重组质粒pEGFP-C1-hri,用脂质体法将其瞬时转染到小鼠黑色素瘤细胞B16中,在荧光显微镜下检测其表达。结果pEGFP-C1-hri中插入了hri序列,绿色荧光高效表达于B16细胞浆中。结论pEGFP-C1-hri表达载体已成功构建。 Objective To construct the expression vector of human ribonuclease inhibitor fused to green fluorescent protein which was capable of expression in ceils and to provide a useful tool for investigation the molecular mechanism of antitumor effects from hri. Methods Hri in pGEX-6p-1-hri vector was subcloned into the green fluorescent protein vector pEGFP-C1. The recombinant plasmid was then transfected into mouse B16 Melanoma Ceils, followed by observation of the cells by fluorescent microscope. Results It was identified by enzyme digestion successfully that construction of the recombinant plasmid. The expression of EGFP-hri fusion protein was confirmed by fluorescent microscope. Conclusions pEGFP-hri fusion gene vector is successfully constructed and the fusion protein can be expressed in cytomatrix of B16 cells
出处 《中国微生态学杂志》 CAS CSCD 2006年第5期371-372,共2页 Chinese Journal of Microecology
基金 大连市卫生局医学科研基金资助课题(200510)
关键词 人核糖核酸酶抑制因子 绿色荧光蛋白 载体 构建 Human ribonuclease inhibitor Green fluorescent protein Vector Construction
  • 相关文献

参考文献5

二级参考文献20

  • 1[1]Sharpiro R.Cytoplasmic ribonuclease inhibitor.In:Abelson JN,Simon MI,eds.Methods in Enzymology.San Diego:Academic Press,2001.611~628
  • 2[2]Papageorgiou A C,Shapiro R,Acharya K R.Molecular recognition of human angiogenin by placental ribonuclease inhibitor.EMBO J,1997,16(17):5162~5177
  • 3[3]Chen C Z,Shapiro R.Site-specific mutagenesis reveals differences in the structural bases for tight binding of RNase inhibitor to angiogenin and RNase A.Proc Natl Acad Sci USA,1997,94(5):1761~1766
  • 4[4]Rybak S M,Sanovich E,Hollingshead M G,et al."Vasocrine"formation of tumor cell- lined vascular spaces:implications for rational design of antiangiogenic therapies.Cancer Res,2003,63(11):2812~2819
  • 5[5]Cuadros C,Dominguez A L,Frost G L,et al.Cooperative effect between immunotherapy and antiangiogenic therapy leads to effective tumor rejection in tolerant Her-2/neu mice.Cancer Res,2003,63(18):5895~5901
  • 6[6]Estrada R B,Malet G,Revert F,et al.Antitumor effect of B16melanoma cells genetically modified with the angiogensis inhibitor RNasin.Cancer Gene Ther,2001,8(4):278~284
  • 7[7]Schneider R,Schneider-Scherzer E,Thurnher M,et al.The primary structure of human ribonuclease/angiogenin inhibitor(RI)discloses a novel highly diversified protein superfamily with a common repetitive module.EMBO J,1988,7(13):4151~4156
  • 8[8]Hofsteenge J.Ribonuclease inhibitor.In:D' Alessio G,Riordan J F,eds.Ribonuclease:Structures and Functions.New York:Academic Press,1997.621~623
  • 9[9]Polakowski I J,Lewis M K,Muthukkaruppan V R,et al.A ribonuclease inhibitor expression anti-angiogenic properties and leads to reduced tumor growth in mice.Am J Pathol,1993,143(2):507~517
  • 10[12]Menna P L,Skilton G S,Leskow F C,et al.Inhibition of aggressiveness of metastatic mouse mammary carcinoma cells by the β2-chimaerin GAP domain.Cancer Res,2003,63(9):2284~2291

共引文献33

同被引文献30

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部